MOUNTAIN VIEW, Calif., Nov. 4, 2010 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended October 2, 2010.
"Our performance improved in the third quarter. Excluding OEM revenue, our Ophthalmology business grew 5.8% from $7.4 million in the third quarter of 2009 to $7.9 million this quarter, and it was most rewarding to see our ophthalmology consumable revenues return to growth. Consumables are an important part of our overall growth strategy as are strategic acquisitions," stated Mr. Theodore A. Boutacoff, President and CEO. "Gross margin was above our guidance range due to favorable product mix and volume efficiencies and we continue to manage our operating expenses well."
"Our largest trade show, the Annual Meeting of the American Academy of Ophthalmology, was in October and we were extremely pleased with the improved business activity at the Academy with sales and leads generated at this meeting increasing significantly over the prior year, which we believe is indicative of a turnaround in the worldwide economies and an increasing interest in our wider product offering," continued Mr. Boutacoff.
"Customers expressed particular interest in our new IQ577 and IQ532 laser systems and in performing tissue sparing laser photocoagulation using our MicroPulse™ technology. The interest in MicroPulse technology was stimulated by excellent results reported in recently published clinical studies. We see tissue sparing laser therapy as a true paradigm shift providing patients suffering from diseases such as diabetic macular edema (DME) with the clinical benefits of laser photocoagulation without damaging the retina. The adoption of tissue sparing treatments has the potential to drive up demand for new laser systems that are tissue sparing capable and IRIDEX leads the way with its MicroPulse technology."
Q3 Business Highlights:
Conference Call IRIDEX management will conduct a conference call later today, Thursday, November 4, 2010 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (800) 762-9441(U.S.) or (480) 629-9674 (International) and quoting Conference ID 4380709, or by visiting the Company's website at www.iridex.com. A telephone replay will be available beginning on Thursday, November 4, 2010 through Thursday, November 11, 2010 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4380709. In addition, later today an archived version of the webcast will be available on the Company's website at www.iridex.com.
About IRIDEX IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.
Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's fourth quarter revenue, gross margins and operating expenses, the status of the worldwide economy, interest in our products, industry trends relating to the treatment of diabetic macular edema and adoption and success of our product offerings. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2010 and our Quarterly Reports on Form 10-Q for the quarters ended April 3, 2010 and July 3, 2010, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.IRIDEX CorporationCondensed Consolidated Statements of Operations(In thousands, except per share data)
(unaudited)Three Months EndedNine Months EndedOctober 2,October 3,October 2,October 3,2010200920102009Revenues
$ 10,818$ 10,400$ 31,466$ 31,649Cost of revenues
5,2495,12215,01014,999Operating expenses:Research and development
9208882,9132,635Sales and marketing
2,3192,2046,9846,766General and administrative
1,1251,0613,4903,867Total operating expenses
4,3644,15313,38713,268Income from operations
8859691,6231,731 Legal settlement
00800800Interest and other income (expense), net
63(64)(49)(197)Income before income taxes
9489052,3742,334Provision for income taxes
2,068Net income per share - basic
.23Net income per share - diluted
.21Shares used in computing net income per share - basic
8,9748,8458,9308,845Shares used in computing net income per share - diluted
10,1489,90010,11210,003IRIDEX CorporationCondensed Consolidated Balance Sheets(In thousands)
(unaudited)October 2,January 2,20102010Assets(unaudited)Current Assets:Cash and cash equivalents
9,378Accounts receivable, net
9,7828,999Prepaids and other current assets
424470Total current assets
25,25226,329 Property and equipment, net
395486Other long-term assets
234323 Other intangible assets, net
28,291Liabilities and Stockholders' EquityCurrent Liabilities:Accounts payable
,872Bank line of credit
2,2392,405Total current liabilities
9,19513,116Long Term Liabilities:Other long-term liabilities
9,78013,265Stockholders' Equity: Convertible preferred stock
8989Additional paid-in capital
41,00539,820Accumulated other comprehensive loss
(212)(212)Treasury stock, at cost
(22,037)(24,246)Total stockholders' equity
18,42015,026Total liabilities and stockholders' equity
|SOURCE IRIDEX Corporation|
Copyright©2010 PR Newswire.
All rights reserved